JACKSONVILLE, Fla., March 22, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that it will participate in two upcoming Investor and Industry conferences.
Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company's business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, NY. Additionally, Dr. Wilson will serve as a panelist during the conference's "Cancer Vaccines: Immuno-Priming and Tumor Antigens" panel discussion.
Concurrently, Dr. John Bonfiglio, President and Chief Operating Officer of TapImmune, will provide an overview of the company's unique approach during a presentation titled "Synthesis, Purification and Formulation of a New T Cell Vaccine Using 5 Novel Proteins," during the S2 Oligonucleotide & Peptide Therapeutics Boston Conference in Boston, MA.
|
Event: |
Sachs' 5th Annual Cancer Biopartnering & Investment Forum | |
|
Date: |
Tuesday, March 28, 2017 | |
|
Times: |
Company presentation: 10:35 am (Eastern Time) Cancer vaccine panel discussion: 2:00 pm (Eastern Time) | |
|
Location: |
The New York Academy of Sciences, New York, NY | |
|
Event: |
S2 Oligonucleotide & Peptide Therapeutics Boston Conference | |
|
Date: |
Wednesday, March 29, 2017 | |
|
Time: |
1:30 pm (Eastern Time) | |
|
Location: |
Royal Sonesta Boston, Cambridge, MA |
The presentation of the Sachs' 5th Annual Cancer Biopartnering & Investment Forum will be webcast live and will remain available as an archive following the presentation. To access the webcast, please visit the events page section of the TapImmune website at http://tapimmune.com/events/.
About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman's cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.
Please visit the company's website at www.tapimmune.com for more details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The company assumes no obligation to update the forward-looking statements.
SOURCE TapImmune, Inc.
